Cargando…
An Attempt to Develop a New Treatment Strategy for Rare Refractory Gynecological Malignancies: The Japanese Gynecologic Oncology Group
Platinum-based combination chemotherapy has been a frontline therapeutic strategy for advanced ovarian cancer. Although patients with ovarian high-grade serous carcinoma (HGSC) respond well to the combination therapy, those with relatively rare histologic subtypes, such as mucinous or clear cell car...
Autores principales: | Shigeta, Shogo, Shimada, Muneaki, Suzuki, Shiro, Kajiyama, Hiroaki, Oda, Katsutoshi, Takehara, Kazuhiro, Mandai, Masaki, Aoki, Daisuke, Enomoto, Takayuki, Okamoto, Aikou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627836/ https://www.ncbi.nlm.nih.gov/pubmed/37941704 http://dx.doi.org/10.31662/jmaj.2023-0024 |
Ejemplares similares
-
An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group
por: Shimada, Muneaki, et al.
Publicado: (2023) -
Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)
por: Kobayashi, Yusuke, et al.
Publicado: (2022) -
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
por: Asano, Hiroshi, et al.
Publicado: (2022) -
Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study
por: Machida, Hiroko, et al.
Publicado: (2021) -
East Asian Gynecologic Oncology Trial Group (EAGOT): founding history and future perspective
por: Enomoto, Takayuki, et al.
Publicado: (2023)